Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
On Friday, Merck & Co Inc (NYSE:MRK) agreed to acquire CN201, an investigational clinical-stage bispecific antibody for B-cell-associated diseases, from privately-held Curon Biopharmaceutical.
默沙东公司于周五同意从私人持有的Curon生物制药公司收购CN201，这是正在临床研究的针对b细胞相关疾病的 bispecific antibody。
"We continue to identify opportunities to expand and diversify our pipeline," said Dr. Dean Y. Li, president of Merck Research Laboratories. "Early clinical data have provided robust evidence for the potential of CN201 to target and deplete circulating and tissue B cells with the potential to treat a range of malignant and autoimmune diseases."
“我们继续寻找扩大和多元化我们的流水线的机会，”默沙东研究实验室总裁德恩Y. 李博士表示。 “早期的临床数据已经提供了CN201具有潜力通过靶向和清除循环和组织b细胞来治疗一系列恶性和自身免疫性疾病的强有力证据。”
Merck will acquire full global rights to CN201 for an upfront payment of $700 million in cash.
默沙东将以现金70000万美元的前期费用全球收购CN201的所有权利。
Curon is also eligible to receive up to $600 million in milestone payments.
Curon还有资格获得最高60000万美元的里程碑奖金。
CN201 is currently being evaluated in Phase 1 and Phase 1b/2 trials for relapsed or refractory non-Hodgkin's lymphoma and B-cell acute lymphocytic leukemia, respectively.
CN201目前正在进行1期和1b/2期试验，用于复发或难治的非何杰金淋巴瘤和b细胞急性淋巴细胞白血病的治疗。
Merck plans to evaluate CN201 as a treatment for B-cell malignancies and investigate its potential for autoimmune diseases.
默沙东计划将CN201作为b细胞恶性肿瘤的治疗方案，并调查其在自身免疫性疾病中的潜力。
The transaction is expected to close in the third quarter of 2024. Merck expects to record a pre-tax charge of approximately $750 million, or approximately $0.28 per share, to be included in adjusted results.
本次交易预计将于2024年第三季度关闭。默沙东预计将在调整后的结果中录得约7,500万美元的税前费用，或约每股0.28美元。
Also Read: Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects.
此外阅读：由于无效的结果和副作用，默克停止肺癌研究的Keytruda组合。
William Blair writes that the deal is relevant to Cullinan Therapeutics Inc.'s (NASDAQ:CGEM) CLN-978, which is expected to enter clinical trials in systemic lupus erythematosus and rheumatoid arthritis.
William Blair表示，本次交易与Cullinan Therapeutics Inc. (NASDAQ: CGEM)的CLN-978有关，并且预计后者将进入系统性红斑狼疮和类风湿性关节炎的临床试验。
CN201 is a CD19xCD3 bispecific, and the analyst says the deal supports its potential in treating autoimmune diseases. The analyst also highlighted the appealing valuation of Cullinan, which is currently valued at under $300 million.
CN201是CD19xCD3的bispecific，分析师表示，该交易支持其在治疗自身免疫性疾病方面的潜力。分析师还强调了Cullinan的吸引力估值，目前估值不到3亿美元。
As competition intensifies in the CD19 autoimmune sector, William Blair sees less rivalry in the CD19 bispecific arena than cell therapies, presenting a substantial opportunity for Cullinan.
随着CD19自身免疫领域的竞争加剧，William Blair认为，在CD19 bispecific领域中的竞争相对较小，而该领域相对于细胞疗法来说具有很大的机会，这为Cullinan提供了巨大的机遇。
The analyst reiterates the Outperform rating on Cullinan shares.
分析师重申对Cullinan股票的跑赢市场评级。
Price Action: CGEM stock is up 3.66% at $16.98, and MRK stock is up 0.31% at $114.27 at the last check on Friday.
在上周五的最后检查时，CGEM股票上涨3.66%，报16.98美元，MRk股票上涨0.31%，报114.27美元。
- Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst
- 银休特的胰岛素泵制造商成长催化剂预计将在2025年提高收益：分析师
Photo Courtesy Merck
照片由默克提供。